Aspira Pathlab

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 26-Jun, Aspira Pathlab & Diagnostics Ltd's stock is currently at Rs 131.25, having risen by 1.98% and significantly outperforming the Sensex over various periods, including a year-to-date increase of 98.32%. Despite a drop in investor participation, the stock shows strong performance metrics and remains liquid for trading.

As of 26-Jun, Aspira Pathlab & Diagnostics Ltd's stock price is rising, currently at Rs 131.25, reflecting an increase of Rs 2.55 or 1.98%. The stock has shown strong performance over various periods, with a 7.58% increase over the past week, significantly outperforming the Sensex, which declined by 0.40% during the same timeframe. Over the past month, the stock has risen by 10.39%, while the Sensex has only increased by 0.80%. Year-to-date, Aspira Pathlab's stock has surged by 98.32%, contrasting sharply with the Sensex's decline of 9.53%. <BR><BR>Additionally, the stock is close to its 52-week high, just 3.53% away from Rs 135.88, and has been on a consecutive gain streak for the last four days. It has consistently traded above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. However, it is important to note that there has been a significant drop in investor participation, with delivery volume falling by 93% compared to the 5-day average. Despite this decline in participation, the stock remains liquid enough for trading, suggesting that the current rise is supported by strong performance metrics rather than high trading volume.

Which are the latest news on Aspira Pathlab?

What does Aspira Pathlab do?

Aspira Pathlab & Diagnostics Ltd is a micro-cap pathology specialist in healthcare, incorporated in 1973, with recent net sales of 7 Cr and a net profit of -1 Cr as of March 2026. The company has a market cap of INR 127 Cr and key metrics include a P/E of 52.00 and a debt-equity ratio of 0.13.

Overview: <BR>Aspira Pathlab & Diagnostics Ltd is a leading pathology specialist in the healthcare services industry, operating within the micro-cap market.<BR><BR>History: <BR>Incorporated in July 1973, Aspira Pathlab has maintained its status as a prominent player in the pathology sector. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 7 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 127 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 52.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.13 <BR>Return on Equity: 0.49% <BR>Price to Book: 10.35<BR><BR>Contact Details: <BR>Address: Flat No. 2 RD Shah Building, Shraddanand Road Ghatkopar(W) Mumbai Maharashtra : 400086 <BR>Tel: 91-22-71975756/5656 <BR>Email: info@aspiradiagnostics.com/urkalsoa <BR>Website: http://www.aspiradiagnostics.com

How big is Aspira Pathlab?

As of 10th June, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 127.00 Cr, with net sales of 22.62 Cr and a net profit of 2.40 Cr over the latest four quarters. The company reported shareholder's funds of 12.17 Cr and total assets of 17.46 Cr for March 2025.

As of 10th June, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 127.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Aspira Pathlab reported Net Sales of 22.62 Cr and a Net Profit of 2.40 Cr.<BR><BR>For the reporting period of March 2025, the company had Shareholder's Funds amounting to 12.17 Cr and Total Assets of 17.46 Cr.

Who are in the management team of Aspira Pathlab?

The management team of Aspira Pathlab includes Pankaj Jashwant Shah (Managing Director & CEO), Haseeb Drabu (Chairman), and several directors, including independent directors and a company secretary, responsible for the company's strategic direction and management.

The management team of Aspira Pathlab includes the following key members:<BR><BR>1. **Pankaj Jashwant Shah** - Managing Director & CEO<BR>2. **Arvind Karsandas Bhanushali** - Executive Director<BR>3. **Arvind Karsandas Bhanushali** - Non-Executive Director<BR>4. **Haseeb Drabu** - Chairman<BR>5. **Nikunj Mange** - Director<BR>6. **Mangala Radha Krishnan Prabhu** - Independent Director<BR>7. **Subhash Raghunath Salunke** - Independent Director<BR>8. **A C Mahajan** - Independent Director<BR>9. **Priya Pandey** - Company Secretary<BR><BR>This team is responsible for the strategic direction and management of the company. If you need more specific information about any of the members or their roles, feel free to ask!

Who are the peers of the Aspira Pathlab?

Aspira Pathlab's peers include Star Imaging, Jeevan Scienti., Bilcare, Choksi Laborator, Royal Sense, Aakaar Medical, and QMS Medical. Aspira Pathlab has a 1-year return of 100.85%, outperforming its peers, with the highest return from Jeevan Scienti. at 95.63% and the lowest from Choksi Laborator at -35.73%.

Peers: The peers of Aspira Pathlab are Star Imaging, Jeevan Scienti., Bilcare, Choksi Laborator, Royal Sense, Aakaar Medical, and QMS Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Star Imaging, while Good management risk is found at Royal Sense and Aakaar Medical. Below Average management risk is present at Jeevan Scienti., Bilcare, Aspira Pathlab, Choksi Laborator, and QMS Medical. Growth is Excellent at Royal Sense, Good at Choksi Laborator and Aakaar Medical, and Below Average at Star Imaging, Jeevan Scienti., Bilcare, Aspira Pathlab, and QMS Medical. Capital Structure is Excellent at Star Imaging, Good at Royal Sense, Aakaar Medical, and Average at Aspira Pathlab, while Below Average is noted for Jeevan Scienti., Bilcare, Choksi Laborator, and QMS Medical.<BR><BR>Return Snapshot: Aspira Pathlab has a 1-year return of 100.85%, while the highest 1-year return among peers is 95.63% from Jeevan Scienti. and the lowest is -35.73% from Choksi Laborator. Aspira Pathlab's return is significantly higher than that of Choksi Laborator. Additionally, Royal Sense and Choksi Laborator have negative six-month returns.

Should I buy, sell or hold Aspira Pathlab & Diagnostics Ltd?

When is the next results date for Aspira Pathlab & Diagnostics Ltd?

The next results date for Aspira Pathlab & Diagnostics Ltd is 23 May 2026.

The next results date for Aspira Pathlab & Diagnostics Ltd is scheduled for 23 May 2026.

Are Aspira Pathlab & Diagnostics Ltd latest results good or bad?

Aspira Pathlab & Diagnostics Ltd's latest results show strong year-on-year growth, with a 740% increase in net profit and a 13.15% rise in revenue. However, there are concerns due to a decline in both revenue and net profit compared to the previous quarter, indicating potential challenges in sustaining growth.

Aspira Pathlab & Diagnostics Ltd's latest results present a mixed picture. On one hand, the company has shown significant year-on-year growth, with a net profit of ₹0.42 crore in Q1 FY26, which is a remarkable increase of 740% compared to the same quarter last year. Revenue also rose by 13.15% year-on-year to ₹5.25 crore. Additionally, the operating margin improved to 13.9%, up 8.08 percentage points from the previous year.<BR><BR>However, the quarter-on-quarter performance raises concerns. Both revenue and net profit declined sequentially, with revenue down 9.17% and net profit down 38.24% from the previous quarter. This decline in performance suggests potential challenges in sustaining the recent growth momentum. <BR><BR>Overall, while the year-on-year improvements indicate a recovery from previous losses, the recent quarter's sequential declines point to volatility and uncertainty regarding the company's operational sustainability. Thus, the results can be seen as good in the context of year-on-year growth but concerning when considering the recent quarterly performance.

How has been the historical performance of Aspira Pathlab?

Aspira Pathlab's financial performance improved significantly from March 2024 to March 2025, with net sales rising to 22.00 Cr from 13.20 Cr, and a turnaround from losses to a profit after tax of 2.02 Cr. Key metrics such as EPS and operating profit margin also showed positive growth, indicating a strengthened financial position.

Answer:<BR>Aspira Pathlab has shown significant improvement in its financial performance from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Aspira Pathlab reported net sales of 22.00 Cr, a notable increase from 13.20 Cr in the previous year. Total operating income also rose to 22.00 Cr from 13.20 Cr, while total expenditure increased to 18.83 Cr from 14.76 Cr. This led to an operating profit (PBDIT) of 3.56 Cr, a recovery from a loss of 1.14 Cr in the prior year. Profit before tax improved to 2.07 Cr from a loss of 2.67 Cr, resulting in a profit after tax of 2.02 Cr compared to a loss of 2.67 Cr previously. The earnings per share (EPS) turned positive at 1.96, up from a negative 2.59. The operating profit margin also saw a significant turnaround, reaching 14.41% from -11.82%, while the profit after tax margin improved to 9.18% from -20.23%. On the balance sheet, total assets increased to 17.46 Cr from 14.71 Cr, with total liabilities rising to 17.46 Cr from 14.71 Cr. The book value per share improved to 7.03 from 5.07, indicating a strengthening financial position. Cash flow from operating activities remained stable at 1.00 Cr, with a closing cash equivalent of 1.00 Cr, up from none in the previous year.

Who are the top shareholders of the Aspira Pathlab?

The top shareholders of Aspira Pathlab are Deepali Arvind Bhanushali with 8.6% and Rinku Vinod Bhanushali with 8.1%. Individual investors own 60.46% of the shares, with no mutual funds or foreign institutional investors involved.

The top shareholders of Aspira Pathlab include Deepali Arvind Bhanushali, who holds the highest promoter stake at 8.6%. Following her, the highest public shareholder is Rinku Vinod Bhanushali, with a holding of 8.1%. Additionally, individual investors collectively own a significant portion of the company, accounting for 60.46% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Is Aspira Pathlab overvalued or undervalued?

As of May 19, 2025, Aspira Pathlab is considered very attractive due to its strong performance metrics, including a PE ratio of 27.85 and a PEG ratio of 0.16, indicating it is undervalued compared to peers like Dr. Lal PathLabs and Metropolis Healthcare, despite recent underperformance against the Sensex, with a notable 107.67% return over the past year.

As of 19 May 2025, the valuation grade for Aspira Pathlab has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently undervalued based on its strong performance metrics. Key ratios include a PE ratio of 27.85, an EV to EBITDA of 16.26, and a PEG ratio of 0.16, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Aspira Pathlab's valuation stands out, particularly against companies like Dr. Lal PathLabs, which has a PE ratio of approximately 40, and Metropolis Healthcare, with an EV to EBITDA of around 25. The robust ROCE of 18.34% and ROE of 18.63% further reinforce the company's strong operational efficiency. While the stock has underperformed the Sensex in shorter time frames, its impressive 107.67% return over the past year highlights its potential for growth, supporting the conclusion that Aspira Pathlab is currently undervalued.

What is the technical trend for Aspira Pathlab?

As of April 2, 2025, Aspira Pathlab's trend is mildly bullish, with mixed signals from key indicators like MACD and Bollinger Bands across different time frames.

As of 2 April 2025, the technical trend for Aspira Pathlab has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating some weakness in momentum. The daily moving averages are mildly bullish, suggesting short-term support. The Bollinger Bands show a mildly bearish stance on the weekly chart but bullish on the monthly, indicating mixed signals across time frames. The KST is bearish weekly but bullish monthly, adding to the complexity of the trend. Overall, the current stance is mildly bullish, with key indicators highlighting mixed momentum and trend signals across different time frames.

Has Aspira Pathlab declared dividend?

No Dividend History Available